![Nicholas Cross](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Nicholas Cross
Chairman at Accession Therapeutics Limited
Nicholas Cross active positions
Companies | Position | Start | End |
---|---|---|---|
Accession Therapeutics Limited
![]() Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors. | Chairman | - | - |
Career history of Nicholas Cross
Former positions of Nicholas Cross
Companies | Position | Start | End |
---|---|---|---|
Avidex Ltd.
![]() Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Director/Board Member | 2005-12-31 | 2008-12-03 |
IMMUNOCORE HOLDINGS PLC | Director/Board Member | 2007-12-31 | - |
Founder | 2007-12-31 | - | |
Oxford Asymmetry International Plc | Chairman | - | - |
Oxxon Therapeutics, Inc.
![]() Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | Director/Board Member | - | - |
Statistics
International
United Kingdom | 6 |
Operational
Director/Board Member | 3 |
Chairman | 2 |
Founder | 1 |
Sectoral
Health Technology | 5 |
Process Industries | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
IMMUNOCORE HOLDINGS PLC | Health Technology |
Private companies | 4 |
---|---|
Oxford Asymmetry International Plc | Process Industries |
Avidex Ltd.
![]() Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Health Technology |
Oxxon Therapeutics, Inc.
![]() Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | Health Technology |
Accession Therapeutics Limited
![]() Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors. | Health Technology |
- Stock Market
- Insiders
- Nicholas Cross
- Experience